Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
and computational chemistry and this Hub will promote connectivity of the broader community, training, networking, as well as state-of-the-art research. This post will develop artificial intelligence
-
will develop and apply methods to transform omics data into networks and executable models, collaborating closely with experts across the Petsalaki and Sheriff groups, Open Targets, EMBL-EBI, and the
-
possible. We strive to ensure the diversity of our candidates, and we reflect this ethos in the way we promote the ICRF programme and in our recruitment and selection process. Imperial’s diversity networks
-
Duties The responsibilities may include some but not all of the responsibilities outlined below. Implement and test different Artificial Neural Network (ANN) architectures, such as convolutional and
-
academic, clinical, and industry partnerships, as well as global networks, we translate biological insights into innovations for early detection, individualized therapies, and disease prevention. Founded in
-
requirements and use resources effectively Learn and keep abreast of latest technological, methodological and software developments Understanding of, and ability to contribute to, broader management
-
development, mentoring, and scientific networking * Remuneration: according to TV-L, including a fixed annual special payment and a company pension scheme * Vacation: 30 days of paid leave; Christmas Eve and
-
project managing research to deliver high quality results. Ability to communicate complex information clearly, to a wide audience. Strong report-writing and proposal-writing skills. Confidence in networking
-
/software monitoring etc Demonstrate an understanding of practical applications of bioinformatics for immunological or inflammation research Ability to assess resource requirements and use resources
-
of the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). We are seeking scientists to lead research projects with a specific focus on the genetic determinants of severe adverse drug and vaccine reactions